Could Entos Pharmaceuticals’ Fusogenix platform open a real path to treatment in L-CMD?
Entos Pharmaceuticals and the L-CMD Research Foundation are targeting a curative L-CMD therapy. Read what this could change for rare disease treatment.
Entos Pharmaceuticals and the L-CMD Research Foundation are targeting a curative L-CMD therapy. Read what this could change for rare disease treatment.